



Cite this: *Chem. Commun.*, 2020, **56**, 15360

Received 1st October 2020,
Accepted 10th November 2020

DOI: 10.1039/d0cc06583h

rsc.li/chemcomm

Cucurbiturils in nucleic acids research

Ekaterina Y. Chernikova *^a and Daria V. Berdnikova *^b

During the past ten years, the importance of cucurbiturils (CB[n]) as macrocyclic hosts in supramolecular assemblies with various types of natural and synthetic nucleic acids (NAs) has increased explosively. As a component of such systems, CB[n] macrocycles can play a wide spectrum of roles from drug and gene delivery vehicles to catalysts/inhibitors of biochemical reactions and even building blocks for NA-based materials. The aim of this highlight article is to describe the development of the CB[n] applications in nucleic acids research and to outline the current situation and perspectives of this fascinating synergistic combination of supramolecular chemistry of CB[n] and NAs.

1. Introduction

Nucleic acids (NAs) such as deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) are central molecular scaffolds in almost

all living organisms.¹ Apart from their fundamental role as carriers of genetic information provided by DNA and viral RNA, nucleic acids are also responsible for intracellular recognition, transport and catalysis that is accomplished by various types of RNA. Along with extensive investigations of the properties and functions of naturally occurring nucleic acids, synthetic and chemically modified oligonucleotides are also attracting significant attention for the development of innovative diagnostic and therapeutic approaches in biology, medicine and materials science.^{2–5}

^a Laboratory of Photoactive Supramolecular Systems, A. N. Nesmeyanov Institute of Organoelement Compounds of Russian Academy of Sciences, Vavilova St. 28, Moscow, Russia. E-mail: chernikova@ineos.ac.ru

^b Department Chemie-Biologie, Organische Chemie II, Universität Siegen, Adolf-Reichwein-Str. 2, 57076 Siegen, Germany
E-mail: berdnikova@chemie-bio.uni-siegen.de




Ekaterina Y. Chernikova

Dr Ekaterina Y. Chernikova studied chemistry at M. V. Lomonosov Moscow State Academy of Fine Chemical Technology (Moscow, Russia) where she obtained her Bachelor's degree (2005) and Master's degree (2007) in chemical technology and biotechnology. In 2011, she received her PhD in physical chemistry at A. N. Nesmeyanov Institute of Organoelement Compounds of Russian Academy of Sciences (INEOS RAS). After completion of PhD up to now, she is working as a senior researcher at INEOS RAS in the Laboratory of Photoactive Supramolecular Systems. Her research interests are focused on the development of supramolecular assemblies and photochemical systems based on the organic chromophores and cucurbiturils.



Daria V. Berdnikova

Dr Daria V. Berdnikova obtained her Chemical Engineer degree (2009) with specialization in nanomaterials at D. I. Mendeleev University of Chemical Technology of Russia (Moscow, Russia). In 2012, she received her PhD in organic chemistry and physical chemistry at A. N. Nesmeyanov Institute of Organoelement Compounds of Russian Academy of Sciences (INEOS RAS). In 2013–2017, she worked as a senior researcher at INEOS RAS. In 2017, she moved to the University of Siegen (Germany), as a Marie Skłodowska Curie fellow. Since 2020, she is a leader of the independent DFG project at the University of Siegen. Her research interests include design and synthesis of DNA- and RNA-targeting ligands, controllable interactions of photoactive molecules with nucleic acids and supramolecular assemblies.



Highlight



Scheme 2 Structures of cationic dendrimers **8–10**, the galactosylated cucurbit[6]uril (gCB[6]), bis-naphthalene-derivatized Ru(bpy)₃ guests **11a** and **11b** and their supramolecular assembly in CB[8] cavity.

In 2002, K. Kim and co-workers obtained a noncovalent complex of CB[6] with poly(propyleneimine) (PPI) dendrimer modified by diaminobutane-terminated groups **8** (Scheme 2).³⁷ In this system, CB[6] encapsulated cationic fragments of the dendrimer **8** to form stable pseudorotaxanes. This gene delivery system was tested for compaction of pEGFP-Luc plasmid DNA (pDNA). *In vitro* studies using Vero 76 and 293 mammalian cell lines showed relatively low toxicity of **8**-CB[6] with about 50% of the cells remaining viable even at high concentrations of the complex ($c = 100 \mu\text{g mL}^{-1}$). The transfection efficiency of the supramolecular polyplex increased with increasing dendrimer generation number from G3 to G5 and reached values of *ca.* 10 times lower than those of well-known poly(ethyleneimine) (PEI) carriers, which was probably related to the reduced flexibility due to the threading of macrocyclic CB[6].

Later in 2018, R. Wang and co-workers also utilized the CB[*n*]-based strategy to reduce the inherent cytotoxicity of the PEI gene vector **9** with a large molecular weight (25 kDa, branched) (Scheme 2).³⁸ For this propose, the supramolecular nanoparticles **9**-pDNA and **9**-CB[7]-pDNA with an average size of 251 nm and 174 nm, respectively, were prepared. An MTT assay in the absence and presence of CB[7] on three different human cell lines (HEK293, 293T, A549) revealed that CB[7] significantly reduced the cytotoxicity of PEI **9** in a dose-dependent manner. Apoptosis analysis with 293T cells with **9**-pDNA and **9**-CB[7]-pDNA showed that complexation with CB[7] markedly inhibited the rate of PEI-induced apoptosis. Additionally, it was found that CB[7] significantly alleviated the hemolytic activity of PEI. Confocal fluorescence microscopy and flow cytometry studies of the PEI-Cy5 conjugates in 293T cells clearly showed that complexation with CB[7] had just a minor effect on the cellular uptake. The efficiency of gene delivery of **9**-pDNA moderately increased in the presence of CB[7] that was attributed to the improved biocompatibility of PEI upon encapsulation by CB[7].

Another work of K. Kim and co-workers describes a target-sensitive delivery system for the transfer of the genetic material into hepatocytes based on the galactose-linked CB[6] (Scheme 2).³⁹ In this system, dextran functionalized with spermine side chains **10** was responsible for the biodegradability as well as effective condensation of pDNA. Self-assembly of the galactosylated CB[6] (gCB[6]) with the conjugate **10** was provided by formation of the strong inclusion complexes between gCB[6] and spermine residues on the dextran backbone (Scheme 2). It was found that the amount of gCB[6] bound to the polyplex significantly influenced the efficiency of pDNA condensation by reducing the amount of available spermine binding sites for the electrostatic attraction to pDNA. For the same reason, gCB[6] can decrease to some extent the affinity of the polyplex towards a negatively charged cell surface. By systematic alternation of several parameters, including the molar ratios of **10**/gCB[6] and spermine nitrogen/pDNA phosphate, the optimized DNA-encapsulating delivery systems were identified. The delivery of the loaded pDNA was tested on the human hepatoma cells HepG2 bearing the galactose-specific asialoglycoprotein receptors (ASGPR). A control competition assay with free galactose and HeLa cells that did not contain ASGPR receptors confirmed that **10**-(gCB[6])₂₅ polyplex with the molar ratio of 25 exhibited target-specific interaction with HepG2 cell surface and enhanced gene transfection efficiency.

In addition to commonly used dendrimer-DNA complexes, several studies were focused on the development of novel types of vector delivery systems. Particularly, Y. Liu and co-workers reported a multifunctional supramolecular assembly consisting of the bis-naphthalene-derivatized Ru(bpy)₃ complexes **11a** and **11b** as guests and CB[8] as a host (Scheme 2).⁴⁰ The encapsulation of the naphthalene units in the CB[8] cavity yielded the water-soluble linear supramolecular dimer (**11a**)₂-CB[8] or polypseudorotaxane (**11b**-CB[8])_{*n*} with high molecular weight. As a gene delivery system, the polypseudorotaxane assembly



Highlight



Scheme 4 Structures of the photoresponsive redox guests **26–31** applied in the CB-based systems for DNA photocleavage.

Apart from light-induced generation of ROS by the viologen radical, covalent attachment of $\text{Ru}(\text{bpy})_3^{2+}$ in **28a–28c** allows to recruit an additional mechanism of the DNA damage by the generation of the oxidized Ru^{3+} through the photoinduced intramolecular ET from Ru^{2+} to the viologen residue. Consequently, Ru^{3+} oxidizes guanine nucleobases and photocleave DNA without generating ROS. The increase of the alkyl spacer length in **28a–28c** allows to improve the photocleavage efficiency by extending the lifetime of the charge transfer state. Encapsulation of the viologen moiety by CB[8] in 1 : 1 complex further inhibits the intramolecular electron back transfer in the conjugates **28a–28c** resulting in a relatively long-living charge transfer oxidation state ($t \sim 2$ ms), which improves the photocleavage efficiency.⁶¹

Conjugates of viologen with aromatic hydrocarbons **29a–29d** (Scheme 4) show a different behaviour.⁶² Thus, 2-anthryl **29c** and 1-pyrenyl **29d** derivatives bind to ct DNA through a mixed binding mode and both of them induce pronounced cleavage of plasmid pBR322 DNA upon irradiation with a xenon lamp. At the same time, phenyl **29a** and 2-naphthyl **29b** derivatives do not interact with DNA. However, upon complexation with CB[8] yielding 1 : 1 complexes, all compounds **29a–29d** exhibit efficient DNA photocleavage. As discussed above, the reason of this effect is encapsulation-induced inhibition of the intramolecular backwards ET in the conjugates that extends the lifetime of the charge separated excited state. Overall, X. Peng and colleagues clearly demonstrated the potential application of CB-based host–guest chemistry for DNA photocleavage.

In 2014, Y. Liu and co-workers synthesized and investigated host–guest complexes of photoresponsive azobenzene–viologen conjugates **30** and **31** (Scheme 4).⁶³ Initially, upon association with CB[8], the conjugate molecules adopt a folded conformation with both *E*-azobenzene and viologen moieties immersed in the macrocycle cavity forming a 1 : 1 inclusion complex. Irradiation of **30** and **31** at 365 nm results in the *E–Z* isomerization of the azobenzene fragment followed by the ejection of the viologen residue from the cavity and formation of pseudorotaxanes with different positioning of CB[8]. Thermal or photochemical backwards *Z–E*-isomerization of azobenzene restores the initial loop-shaped structures of the *E–30–CB[8]* and *E–31–CB[8]*. Most notably, the *E*-configured complexes show a remarkable DNA condensation effect on pBR322

plasmid DNA. In contrast, the pseudorotaxane structures *Z–30–CB[8]* and *Z–31–CB[8]* possess no DNA condensation ability but rather display significant DNA cleaving properties upon UV light irradiation. This can be explained by liberation of the viologen residue from the cavity upon isomerization of azobenzene and consequent UV-induced generation of ROS by viologen radical in solution. Overall, host–guest interactions of conjugates **30** and **31** with CB[8] represent an example of the photoswitching between DNA-condensing and DNA-cleaving properties.

A conceptually different application of a photoreaction in the host–guest system involving CB[7], DNA and hydroxypropyl- β -cyclodextrin (HP- β -CD) has been provided by our groups in 2015 and is described in detail in Section 2.7.

2.7. Functional systems comprising a cucurbituril/cyclodextrin pair

Cyclodextrins (CD) represent another important class of macrocyclic host molecules that are widely applied in biochemistry, pharmacy and medicine due to their low toxicity, biocompatibility and chemical stability.^{64,65} In contrast to cucurbiturils with their affinity towards cationic guests, cyclodextrins tend to encapsulate preferentially neutral hydrophobic guests. Hence, simultaneous presence of both macrocycles in one supramolecular system allows to enhance its functionality due to the interplay of orthogonal binding preferences of the hosts. In this section, we describe the examples of assemblies including both CD and CB[*n*] macrocycles and NAs.

In 2015, our groups have developed a supramolecular five-component cascade that allowed to control ligand–DNA interactions in real time by light.⁶⁶ Such a DNA-binding/displacement system has been realized based on a fine balance between different host–guest interactions of the precursor **32** and the photoinduced intercalator **33** with HP- β -CD, dsDNA and CB[7] (Scheme 5). Starting from the encapsulation of precursor **32** by HP- β -CD to provide the delivery of the substrate in aqueous solution, the cascade continues with photoinduced *in situ* formation of the intercalator **33**, its release from the cyclodextrin host and subsequent association with DNA. The final step of the cascade is the removal of **33** from the DNA binding site by CB[7]. Notably, despite the simultaneous presence of several host molecules, each step of the cascade is not affected by



Scheme 5 Association and redistribution equilibria of the precursor **32** and photocyclization product **33** in the presence of HP- β -CD, CB[7] and DNA.



the presence of the non-involved components, thus making this approach potentially applicable for a photocontrolled DNA-targeting therapy. Additionally, this study anticipates the application of CB[n] not only for drug delivery (Section 2.3) but also for drug deactivation/overdose treatment by elimination of the active substance due to complexation with CB[n].

Y. Liu and co-workers have shown that assemblies comprising a CB/CD pair can efficiently provide the condensation of DNA in a controllable way.^{67,68} Condensation of NAs represents one of the key steps in gene therapy that allows to prevent rapid degradation of oligonucleotides by nucleases.⁶⁹ Thus, in 2007, the authors constructed a pseudopolyrotaxane **35** by threading poly(propylene glycol) diamine (PPG4000) through the modified β -cyclodextrins **34** and subsequent assembly with different amounts of CB[6] to give the complexes with various content of the CB[6]-bound alkylammonium pendants (0, 20, 40, 70, 100%) (Fig. 2).⁶⁷ It was found, that the resulting supramolecular assemblies can efficiently provide condensation of pEGFP-C2 plasmid DNA consisting of circular supercoiled DNA (form I) and relaxed circular DNA (form II) into nanoparticles. Depending on the percentage of CB[6], the DNA condensation efficiency of pseudopolyrotaxanes **35** varied nonlinearly reaching the highest value when 70% of the cationic β -CDs in the supramolecular strand were associated with CB[6].

In 2016, the same group developed a more simple, yet efficient DNA condensation system including the CB[6]/ β -CD pair.⁶⁸ Thus, a ternary supramolecular complex was obtained by self-assembly of modified β -cyclodextrin **34**, CB[6] and anthryl adamantane **36** (Fig. 2). Specifically, like in the case of pseudopolyrotaxane **35**, CB[6] associated with the cationic alkylammonium tail of β -CD **34**, whereas the adamantane residue of **36** formed the inclusion complex with the cyclodextrin cavity. It was found that the synergistic effect of the components in the ternary assembly resulted in pronounced condensation of pBR322 plasmid DNA into uniform spherical nanoparticles. At the same time, no obvious condensation effect was observed upon interaction of individual compounds or binary inclusion complexes with DNA, except for the **36**-CB[6] complex that slightly induced DNA-condensation. In 2016, the Liu group also described a supramolecular assembly comprising a CB[6]/ β -CD pair for the condensation and delivery

of siRNA to cancer cells. This system is described in detail in Section 5.

Overall, the supramolecular systems highlighted above mainly include double-helix DNAs obtained from natural sources, such as calf thymus DNA, salmon testes DNA and various types of plasmid DNAs. However, the application of CB[n]-containing assemblies is by no means limited to the canonical double-stranded forms of DNA. Below we collected examples of the CB[n]-based supramolecular systems with G-quadruplex DNA, synthetic and modified DNA oligonucleotides and RNA.

3. G-Quadruplex DNA

G-Quadruplex DNA (G4-DNA) represents one of the non-canonical types of DNA that is formed in G-rich DNA sequences upon stacking of two or more guanine quartets.⁷⁰ In mammalian cells, quadruplex DNA structures participate in several important processes, such as gene suppression, senescence and initiation of the cellular response to DNA damage.⁷¹ Due to the essential biological role of G4-DNA, control of its folding and functions by interaction with exogenous ligands offers new possibilities for biology and medicine. Along these lines, a CB-based approach has been developed that allows to manipulate folding of G4-DNA by supramolecular assembly.

In 2017, X. Zhou and co-workers described the first example of the CB-assisted supramolecular control of G-quadruplex DNA formation.⁷² In this study, the quadruplex-forming oligonucleotide 5'-TTAGGGTTAGGGTTAGGGT-3' (H24) from the human telomere sequence was used. It was shown that azobenzene derivatives **37** and **38** induced folding of the single-stranded H24 oligonucleotide into a parallel G-quadruplex structure (Scheme 6). Addition of CB[7] resulted in the disassembly of the **37**-DNA complexes and subsequent unfolding of the quadruplex due to the translocation of dye **37** to the CB[7] cavity. Introduction of a competitive CB-binder 1-amino-adamantane led to the displacement of ligand **37** from the CB[7] cavity that consequently resulted in the refolding of the G4 structure of the **37**-DNA complex. Therefore, the supramolecular interplay between the DNA-binder, CB[7] and 1-amino-adamantane provided a general principle for the reversible



Fig. 2 Supramolecular systems for DNA condensation comprising a CB/CD pair.



Scheme 6 Governing the folding of G-quadruplex DNA by reversible association of DNA binders **37**–**39** with CB[7].



Highlight

supramolecular switching of the G-quadruplex structure. Notably, the folding/unfolding of the G4-DNA can be performed reversibly over several cycles by repetitive addition of CB[7] and 1-aminoadamantane. It should be noted that in contrast to the piperidine-substituted azobenzene **37**, the trimethylammonium-substituted azobenzene **38** failed to form a stable complex with CB[7], thus making the supramolecular control of the G4 folding impossible. Additionally, the described supramolecular switching was applied to manipulate the enzymatic reaction between thrombin and fibrinogen with a specially designed thrombin inhibitor consisting of two thrombin-binding aptamers connected by H24 DNA sequence. Folding/unfolding of the linker into the quadruplex structure switched the activity of the inhibitor and, therefore, regulated the thrombin-catalysed conversion of fibrinogen to fibrin.

In 2018, P. Hazra and co-workers applied a similar concept for supramolecular G-quadruplex manipulation.⁷³ Like in the previous study, the authors used human telomeric DNA H24 and CB[7] as a molecular container. The antitumor drug topotecan (**39**) was chosen as a mediator of the quadruplex folding (Scheme 6). Complexation of **39** with H24 DNA induced the formation of the G-quadruplex, whereas addition of CB[7] led to the translocation of the ligand to the CB[7] cavity and subsequent quadruplex unfolding. Notably, upon addition of CB[7], the fluorescence of the ligand changed from green to violet due to the transition of topotecan (**39**) from the zwitterionic to cationic form upon translocation from the DNA binding site to the CB[7] cavity because of the CB-induced pK_a shift. Therefore, this system offered an advantage to follow the DNA structural transformations by fluorescence spectroscopy. Overall, these two studies provided a proof-of-principle for the supramolecular control of the G4-DNA structure by competitive interaction of the quadruplex-binding ligands with CB[7]. However, further development of this approach is required to reveal its potential for the practical applications.

4. Synthetic and modified DNA

In this section, we collected the systems comprising epigenetically modified DNAs as well as artificially synthesized sequences that do not have naturally occurring analogues. Some of these studies are focused on the biological functions of DNA, whereas in other ones DNA is utilized as a supramolecular building block without a reference to its biological role.

4.1. CB-Assisted supramolecular sensing and imaging

The nanopore sensing is a powerful analytical method that relies on monitoring of ionic current fluctuations produced by the interactions between the analyte and the binding sites of nanopores.⁷⁴ The frequency of current signatures is used to identify the analyte and quantify its concentration. Since 2015, H.-C. Wu and co-workers are developing a versatile method for nanopore sensing of biologically related analytes based on DNA–CB[7] host–guest probes.^{75–83} In the method developed by H.-C. Wu and co-workers, introduction of the analyte leads to the release or *in situ* formation of the single-stranded DNA



Fig. 3 Schematic representation of the CB-assisted nanopore sensing, including the trapping of the DNA probe, its dissociation, translocation, and CB[7] oscillation in the vestibule of the α -hemolysin nanopore.

(ssDNA) bearing a ferrocene–CB[7] or adamantane–CB[7] complex, referred to as a DNA probe. Threading of the DNA probe through the α -hemolysin (α HL) nanopore results in the dissociation of the host–guest complex and liberation of CB[7] (Fig. 3). Subsequent trapping and oscillation of free CB[7] in the vestibule of α HL produces a unique pattern of the current signature events that endows the detection with very high confidence at the single molecule level. The application of this strategy allowed to detect a large range of analytes of different size and nature, such as vascular endothelial growth factor (VEGF), thrombin, cocaine,⁷⁵ ssDNA, mono-/multivalent antibodies,⁷⁶ microRNA,⁷⁷ and cancer biomarkers,^{78,79} with high levels of sensitivity. Selective epigenetic modification of 5-methylcytosine, 5-hydroxymethylcytosine⁸⁰ and 8-oxo-2'-deoxyguanosine⁸¹ by attachment of the ferrocene–CB[7]⁸⁰ or adamantane–CB[7]⁸¹ complexes allowed to apply the CB-based α HL nanopore sensing to detect the presence of these nucleobases in single-stranded DNA oligonucleotides. Recently, the method was used for simultaneous monitoring of protease activities and local pH values.⁸² Finally, this approach has been applied to determine the binding constants of the host–guest interactions of CB[6] and CB[7] with small molecules and proteins.⁸³ However, the resulting binding constants were not fully consistent with the previously reported data making this method suitable for qualitative analysis only.

CB-Based assemblies with NAs are also useful for the construction of electrochemical sensing systems for biomolecules, which gain increasing popularity due to low costs, reliability, simplicity of exploitation and high sensitivity.⁸⁴ Modification of biosensors by CB[*n*] anchoring offers new opportunities to generate stimulus-responsive surfaces in a reversible manner.⁸⁵ Up to date, two examples of CB[*n*]-functionalized surfaces as analytical tools for prostate and breast cancer diagnostics have been reported. In 2016, F. Zhang and co-workers developed an electrochemical sensing platform on the basis of a CB[7]-modified electrode for the detection of breast cancer susceptibility gene (BRCA) DNA (Scheme 7a).⁸⁶ The recognition of the targeted DNA sequences occurred in two steps: (i) strong host–guest complexation between CB[7] and a ferrocene residue attached to the DNA on the gold nanospheres (FcNS); (ii) homogenous hybridization of a targeted DNA with FcNS and horseradish peroxidase-labeled DNA/Au nanospheres (HRPNS) concatamers. When brought together, FcNS and HRPNS concatamers supplied the gain of the electrochemical signal. The sensitivity of the platform towards target BRCA DNA increased with decreasing number of the mismatched bases reaching the highest level of signal when DNA strands were





Scheme 7 CB-Based sensor systems for electrochemical detection of DNA and RNA cancer biomarkers.

fully complementary. The concentration range of the BRCA DNA detection was $1 \times 10^{-7} \text{ M} - 5 \times 10^{-11} \text{ M}$ with the detection limit of 25 pM ($S/N = 3$). Importantly, the responsiveness of the CB[7]-FcNS host-guest system to the pH changes allowed to achieve the moderate recyclability of the sensing platform (80% after 5 cycles).

Later on, host-guest recognition properties of CB[8] were used to construct a biosensor with a remarkable response towards microRNA-182-5p, a prostate cancer biomarker.⁸⁷ Thus, two ssDNAs complementary to the target miRNA were labelled with tryptophane residues (Scheme 7b). A charge-transfer complex between CB[8] and methyl viologen (V^{2+}) immobilized on the electrode surface was capable to trap the tryptophane-labelled ssDNAs Trp-ssDNA to form strong heteroternary complex CB[8]- V^{2+} -ssDNA. At last, to trigger an electrochemical signal, the electrode with the preorganized heteroternary complex was modified by hybridization with ssDNA and introduction of electroactive species $[\text{Ru}(\text{NH}_3)_6]^{3+}$. A redox stimulus led to a one-electron reduction of methyl viologen and expulsion of Trp-ssDNA outside the CB[8] cavity. The reversible assembly and release was possible over 10 cycles, demonstrating excellent stability and regeneration rate. Additionally, the screening of cancer-specific biomarkers showed that this biosensor exhibited high selectivity towards miRNA-182-5p over the interfering species miRNA-21, miRNA-141, and miRNA-155.

In 2018, S. Agasti and co-workers described an interesting approach towards biorthogonal fluorescent imaging in cells and tissues based on highly selective host-guest interaction between CB[7] and 1-aminoadamantane AM.⁸⁸ In particular, the developed method was applied to realize high density DNA labelling for PAINT-based (Points Accumulation for Imaging in Nanoscale Topography) super-resolution imaging of fixed HeLa cells

(Scheme 8). To achieve this, the methanol-fixed cells were treated with CB[7]-conjugated antibodies to target cellular microtubules. Subsequently, an AM-derivatized 11nt-ssDNA strand was incubated with CB[7]-tagged cells for specific DNA immobilization on microtubules through CB[7]-AM interactions. Finally, the complementary ATTO655-conjugated 11nt-DNA was incubated with the cells for the DNA-PAINT imaging. Single molecule blinking was recorded using a 642 nm excitation laser line. As a result, a significant increase in resolution as compared to the diffraction-limited image was observed by visualizing a dense microtubule region. Notably, the CB[7]-aminoadamantane system demonstrated exceptional serum stability and maintained high coupling efficiency even after incubation of the components at 37 °C for 16 h. Overall, the described CB[7] noncovalent label provided a synthetic alternative to the widely applied biotin-streptavidin system with some more advanced features, such as increased imaging resolution.

4.2. Supramolecular regulation and mimicking of biological processes

In 2017, a CB-based supramolecular approach towards reversible control of the enzymatic reactions at 5-formylcytosine



Scheme 8 Principle of the DNA-PAINT imaging of microtubules with a CB[7]-adamantane pair.



Highlight



Scheme 9 Epigenetic labelling of 5-formylcytosine (5fC) sites in DNA with adamantyl residue and complexation with CB[7].

(5fC) sites in DNA has been developed.⁸⁹ The 5fC nucleotide **40** plays an important role in active DNA demethylation and acts as an epigenetic mark in mammals, thus representing an attractive chemical target for the intervention in biological processes. The adamantane derivative bearing a hydroxylamine group **AD** has been developed as a chemical tag providing quantitative and selective labelling of 5fC sites (Scheme 9). CB[7] selectively binds to the adamantyl residue of the modified 5fC-AD nucleotide **41**, however this host-guest interaction does not disrupt the natural hydrogen bonding of nucleobases in DNA duplex. Based on these findings, complexation with CB[7] has been applied for the inhibition of several 5fC-targeting biochemical reactions, such as restriction endonuclease digestion, DNA polymerase elongation, and polymerase chain reaction. The reason for these effects is the steric bulk of CB[7] that prevents enzymes from binding to the DNA substrate to catalyse the corresponding processes. Introduction of a competitive binder 1-aminoadamantane **AM** (Scheme 9) allows to remove the macrocycle from the 5fC-AD site of **41** and re-activate the corresponding enzymatic reactions, thus providing a reversible supramolecular control. Overall, this study outlines a range of potential applications of CB-based systems in epigenetics.

The first example of a covalent cucurbituril-DNA conjugate has been provided in 2017 by J. Jayawickramarajah and L. Issacs with co-workers.⁹⁰ Based on self-assembling DNA-small molecule chimeras, the authors constructed a synthetic transducer that selectively converted binding of adenosine triphosphate (ATP) (biological input) into displacement of a model inhibitor of carbonic anhydrase II (CA-II) **42** from the CB[7] cavity (functional output) (Scheme 10). To design the DNA chimeras, an ATP-binding DNA aptamer was split in two halves. The first part of the aptamer (residues 1–13) **43** was attached to the CB[7] host at the 5' position and the second one (residues 14–27) **44** was tethered to the adamantane residue at the 3' position. The model CA-II inhibitor **42** formed a stable inclusion complex with the CB[7] headgroup. The DNA chimeras **43** and **44** were not complementary to each other, however, in the presence of ATP they formed an ATP-templated non-canonical duplex with the 5' terminus of **43** located in proximity to the 3' terminus of **44**. Such a structure resulted in the formation of a strong host-guest interaction between the CB[7] headgroup of **43** and the adamantane residue of **44** leading to the liberation of guest **42** that consequently inhibited CA-II protein. This system provided an important example of the indirectly triggered release of a biologically active guest from CB[7].

Very recently, a supramolecular platform that mimics a cooperative function of the natural transcription factor pair



Scheme 10 A synthetic transducer based on a split DNA aptamer that converts an ATP binding input into release of the CA-II inhibitor.

has been developed based on the combination of DNA minor groove binders pyrrole-imidazole polyamides (PIP) and a host-guest pair CB[7]-adamantane (Fig. 4).⁹¹ Four types of DNA templates comprising a Widom 601 sequence and PIP-binding sites were constructed and reconstituted to form nucleosomes. Cooperative binding of the host **45** and guest conjugates **46–49** to DNA along with a CB[7]-adamantane complexation increased the DNA recognition length of PIP and allowed versatile binding modes. Additional modification of the host or guest conjugates with an epigenetic modulator (bromodomain inhibitor, not shown on Fig. 4) provided the system with the ability to enhance the level of histone acetylation in nucleosomes. Combination of



Fig. 4 Structures of the host and guest conjugates mimicking a natural DNA transcription factor pair and a scheme of complexation.



the aforementioned properties makes the system perspective for future application in medicine.

4.3. Molecular platforms for mechanistical studies of host-guest interactions

Very recently, O. Seitz and co-workers performed a systematic study to evaluate the distance limits of bivalent interactions with both experimental measurements and statistical mechanics analysis.⁹² As an experimental model, the authors used the host-guest interactions between Cy5-labelled CB[7]-DNA conjugates and Cy3-labelled adamantane-DNA conjugates. CB[7] or adamantane derivatives were attached to DNA duplexes with different spacing between the units (21, 42, 63, 84 or 105 nucleotides) forming the corresponding CB[7] arrays **50** (host arrays) or adamantane arrays (guest arrays) **51**, **52** (Fig. 5). Upon the interaction of the host **50** and guest **51**, **52** arrays, the occurrence of FRET in the Cy3-Cy5 dye pair revealed complexation through CB[7]-adamantane interactions and allowed to determine the dissociation constants. Combination of the experimental data and theoretical modelling led to the following generalizing conclusions on the bivalency limitations: (i) the distance between recognition modules, (ii) the flexibility of the scaffold and (iii) dissociation constant of the monovalent interaction. The usage of two adamantane guests with different binding affinity towards CB[7] (Fig. 5) allowed to deduce that low-affinity receptor-ligand interactions reduce the concentration threshold for switching from bivalent interactions to cross-linking. Overall, these results increase the understanding of the factors that are necessary to design bivalent interactive blocks for biological systems.

In 2019, a DNA-based platform to investigate the mechanical strength of the host-guest interactions in the CB[7]-adamantane system was reported.⁹³ The platform comprised two dsDNA handles, which were tethered to CB[7] **53** and different adamantane derivatives **54**-**57**, respectively (Scheme 11). The dsDNA handles were attached to two optically trapped beads through streptavidin-biotin and digoxigenin-antibody interactions and they were also linked to each other by a polythymidine (T₅₀) spacer. A controllable increase of the distance between the beads allowed to detect a rupture event indicating the disassembly of the host-guest complex. It was found that a positively charged adamantane guest possessed higher mechanical stability (49 pN) than a neutral one (44 pN), which was consistent with the reported binding preferences of CB[7].



Fig. 5 Structures of CB[7]-DNA and adamantane-DNA conjugates **50**-**52** applied for mechanistic studies of the bivalent non-covalent interactions.



Scheme 11 Structures of the building blocks **53**-**57** and mode of action of the DNA-based platform to investigate the mechanical strength of the non-covalent binding in the CB[7]-adamantane complex. The streptavidin-biotin and digoxigenin-antibody connections are highlighted in green and orange, respectively.

Surprisingly, it was additionally found that a hexyl group adjacent to the adamantane residue in **54** and **55** served as a chaperone assisting the formation of the CB[7]-adamantane complex.

4.4. Supramolecular nanomaterials comprising CB[n] and DNA

Although the majority of applications of CB[n] in NA research is focused on biological functions of DNA, there are a few examples of systems comprising DNA as a building block with programmable structure and hybridization. Thus, in 2015, a representative example of all-supramolecular double network hydrogel formed by combination of CB[8]- and DNA-based hydrogels was described.⁹⁴ In general, double network hydrogels consist of two independent hydrogels with contrasting properties that interpenetrate each other providing the resulting material with combined physical properties of the individual components. In this particular case, the double network was constructed by “one pot” mixing of four building blocks, namely a Y-shaped DNA oligomer, a DNA linker, phenylalanine-derivatized carboxymethyl cellulose (CMC-phe) and CB[8] (Scheme 12a). The complementary sequences of the DNA Y-scaffold and DNA linker selectively hybridised to form the first crosslinked network. In parallel, CMC-phe and CB[8] also selectively self-assembled due to the host-guest interactions between phenylalanine and CB[8] yielding the second cross-linked network. Because of its structure, the double network hydrogel had increased mechanical properties and thermal stability. Dynamic supramolecular interactions between the building blocks provided the material with shear-thinning and thixotropic properties. Additionally, the hydrogel possessed a full biodegradability profile as every single network could be targetedly cleaved by the corresponding enzymes, such as nucleases and cellulases. Owing to these properties, this





Fig. 6 Structures of compounds **62–65** used in the supramolecular interactions with CB[*n*] and RNA.

dye **62** allowed to overcome this obstacle. Thus, in contrast to the free dye **62**, the **62**-CB[7]₂ complex penetrated into the cells and the cell nuclei where the ligand was released from CB[7] and selectively stained the ribosomal RNA (rRNA) in the nucleus and cytoplasm. The light-up effect of the dye fluorescence upon binding to rRNA was detected by confocal fluorescence microscopy. Importantly, the majority of the stained cells remained alive indicating low cytotoxicity of both CB[7] and the dye **62**. Another example of fluorescent staining and discrimination of DNA from RNA in solution and HeLa cells with the complex of pyronine Y (**20**) with CB[8] has been described in Section 2.5.

In 2018, H.-C. Wu and colleagues developed a novel method for the selective detection of microRNAs based on triplex molecular beacons and CB[*n*]-assisted nanopore sensing.⁷⁷ Apart from microRNA, this approach has been applied for the detection of a range of small molecules, DNA and proteins and is described in detail in Section 4.1.

Another area of application of CB[*n*]-based assemblies in the RNA field is the design of nanovehicles for the delivery of small interfering RNAs (siRNA). siRNA represents a class of short double-stranded non-coding RNA molecules that participate in the RNA interference process, which is an important mechanism used by an organism to defend against external invasion by inhibiting the expression of specific genes.^{98,99} The propensity of CB[*n*] to form stable inclusion complexes with charged guests was used to construct supramolecular polymeric nanostructures, which could electrostatically absorb siRNA and deliver it to cancer cells.

Very recently, J. Liu and co-workers reported supramolecular polymer nanocapsules resulting from the self-assembly of trivologen derivative **63** and CB[8] (Fig. 6).¹⁰⁰ The high positive charge density allowed the nanocapsules to absorb survivin siRNA electrostatically and deliver it into cancer cells. The *in vitro* studies on MCF-7 breast cancer lines showed good biocompatibility of the system, efficient siRNA transfection and pronounced downregulation of the survivin protein expression. Overall, the association with nanocapsules significantly improved the intracellular uptake and reduced the enzymatic degradation of siRNA providing a promising supramolecular approach for gene therapy.

More complex supramolecular system for siRNA delivery comprising CB[6] and β-CD as macrocyclic hosts has been

recently developed by Y. Liu and co-workers.¹⁰¹ Thus, a ternary assembly of the amphiphilic guest **64** with CB[6] and cyclodextrin-tethered hyaluronic acid **65** (Fig. 6) resulted in the formation of functional nanoparticles that are capable of targeted delivery of siRNA to PC-3 human prostate cancer cells. The CB[6]-induced pK_a shift significantly increased the degree of protonation of the guest's polyamine groups at neutral pH, that played a key role in the electrostatic association of siRNA with the nanoparticles. The hyaluronic acid residues provided the targeting capability because they could be specifically recognized by hyaluronic acid receptors that are overexpressed on the surface of cancer cells. Notably, the transfection efficiency of the system exceeded that of conventional transfection reagents. Overall, these self-assembled nanoparticles provided an elegant example of a supramolecular non-viral vector for targeted delivery and release of siRNA in cancer cells.

6. Conclusions

Starting from the pioneering work by K. Kim and co-workers in 2000 up to now – mainly within the past ten years – the applications of CB[*n*]s in nucleic acids research have significantly developed and expanded. The studies highlighted in this review cover a wide range of areas, such as governing biological processes of DNA, changing DNA morphology, sensing of NA, gene and drug delivery, DNA photocleavage, supramolecular mimicking of biological processes as well as mechanistic studies of non-covalent interactions and design of biocompatible nanomaterials. All the described systems function without interference with the native structure/base pairing of NA and are based on (i) CB[*n*]-assisted tuning of the properties of NA-binding ligands, (ii) non-covalent interactions of CB[*n*] with epigenetically modified sites on NA strands or (iii) covalent attachment of CB[*n*] to a NA. Considering this, we suggest that the cornerstone of the successful development in this area is the absence of the direct interaction between the native structure of nucleic acids and CB[*n*].

The uniqueness of CB[*n*] macrocycles in NA context is enhanced by their ability to cross the cell membrane and to penetrate into the cell nuclei in free state or together with encapsulated guests. This feature points out novel approaches not only for CB[*n*]-assisted drug delivery to NA but also for drug deactivation or/and overdose treatment. Considering this, we were very surprised to find only two reported examples of the CB[7]-based delivery of clinically used drugs to DNA (Section 2.3). Therefore, we assume that in the near future, further development of CB[*n*]-assisted drug delivery to nucleic acids could be extended to existing NA-targeting drugs, in particular, anticancer agents. Apart of drug delivery, the ability of CB[*n*] to cross the cell membrane opens up new perspectives in intracellular NA-sensing and gene transfection.

To sum up, we believe that the large potential of the application of CB[*n*] in the field of NA chemistry is far from being fully explored and realized. Thus, the majority of the reviewed examples are related to the canonical naturally occurring DNAs or synthetic/modified



Highlight

DNA oligonucleotides, whereas the systems including non-canonical naturally occurring DNA structures (G-quadruplex DNA, triplex DNA, etc.) and RNA are just barely explored. Along these lines, we expect the increasing interests of scientists in connecting supramolecular functionality of CB[n] with unique biological functions of the non-canonical therapeutically relevant DNA and RNA. Furthermore, we anticipate future involvement of CB[n] in the development of the RNA-targeting therapy that is currently emerging as a significant alternative or supplement to the existing treatment of viral and bacterial infections, cancer and several RNA-associated genetic diseases.¹⁰² Additionally, we are looking forward to the successful transfer of the elaborated functional systems involving CB[n] and NAs to *in vitro* and *in vivo* conditions for the cases when this has not been accomplished yet. Overall, we hope that this review will be helpful to order and summarize the achievements and provide a basis for new research ideas and discoveries in this exciting field.

Conflicts of interest

There are no conflicts to declare.

Acknowledgements

Generous financial support from Deutsche Forschungsgemeinschaft (project BE 7202/1-1) and Russian Science Foundation (project 19-43-04127) is gratefully acknowledged. We thank Prof. Dr Heiko Ihmels (Universität Siegen, Germany) for the proof-reading of the manuscript and valuable advices.

Notes and references

- Nucleic acids in chemistry and biology*, ed. G. M. Blackburn, M. J. Gait, D. Loakes and D. M. Williams, RSC publishing, Cambridge, 3rd edn, 2006.
- Z. Wu and L. Zhang, *Biomater. Sci.*, 2019, 7, 4944.
- Z. Suo, J. Chen, X. Hou, Z. Hu, F. Xing and L. Feng, *RSC Adv.*, 2019, 9, 16479.
- A. C. Hill and J. Hall, *Mater. Chem. Front.*, 2020, 4, 1074.
- T. MacCulloch, A. Buchberger and N. Stephanopoulos, *Org. Biomol. Chem.*, 2019, 17, 1668.
- M. J. Hannon, *Chem. Soc. Rev.*, 2007, 36, 280.
- D. Shetty, J. K. Khedkar, K. M. Parkad and K. Kim, *Chem. Soc. Rev.*, 2015, 44, 8747.
- W. Liu, S. K. Samanta, B. D. Smith and L. Isaacs, *Chem. Soc. Rev.*, 2017, 46, 2391.
- K. I. Assaf and W. M. Nau, *Chem. Soc. Rev.*, 2015, 44, 394.
- L. Isaacs, *Acc. Chem. Res.*, 2014, 47, 2052.
- D. H. Macartney, *Isr. J. Chem.*, 2011, 51, 600.
- K. I. Kuok, S. Li, I. W. Wyman and R. Wang, *Ann. N. Y. Acad. Sci.*, 2017, 1398, 108.
- D. Das, K. I. Assaf and W. M. Nau, *Front. Chem.*, 2019, 7, 619.
- S. Walker, R. Oun, F. J. McInnes and N. J. Wheate, *Isr. J. Chem.*, 2011, 51, 616.
- J. Liu, Y. Lan, Z. Yu, C. S. Y. Tan, R. M. Parker, C. Abell and O. A. Scherman, *Acc. Chem. Res.*, 2017, 50, 208.
- S. J. Barrow, S. Kaser, M. J. Rowland, J. Barrio and O. A. Scherman, *Chem. Rev.*, 2015, 115, 12320.
- X. Ma and Y. Zhao, *Chem. Rev.*, 2015, 115, 7794.
- X. Zhou, P. Pathak and J. Jayawickramarajah, *Chem. Commun.*, 2018, 54, 11668.
- S. Dun, C. Ottmann, L.-G. Milroy and L. Brunsveld, *J. Am. Chem. Soc.*, 2017, 139, 13960.
- C. Hou, Z. Huang, Y. Fang and J. Liu, *Org. Biomol. Chem.*, 2017, 15, 4272.
- T. G. Zhan and K. D. Zhang, Artificial host molecules modifying biomacromolecules, *Handbook of Macrocyclic Supramolecular Assembly*, Springer, Singapore, 2019.
- K. Igarashia and K. Kashiwagac, *Int. J. Biochem. Cell Biol.*, 2019, 107, 104.
- D.-H. Bae, D. J. R. Lane, P. J. Jansson and D. R. Richardson, *Biochim. Biophys. Acta, Gen. Subj.*, 2018, 1862, 2053.
- A. Kabir, M. Hossain and G. S. Kumar, *J. Chem. Thermodyn.*, 2013, 57, 445.
- K. S. Srivenugopal, D. E. Wemmer and D. R. Morris, *Nucleic Acids Res.*, 1987, 15, 2563.
- H. Kirino, R. Kuwahara, N. Hamasaki and T. Oshima, *J. Biochem.*, 1990, 107, 661.
- L. Yang, S. Wang, T. Tian and X. Zhou, *Curr. Med. Chem.*, 2012, 19, 557.
- H. Isobe, N. Tomita, J. W. Lee, H.-J. Kim, K. Kim and E. Nakamura, *Angew. Chem., Int. Ed.*, 2000, 39, 4257.
- H. Isobe, S. Sato, J. W. Lee, H.-J. Kim, K. Kim and E. Nakamura, *Chem. Commun.*, 2005, 1549.
- C. P. Carvalho, A. Norouzy, V. Ribeiro, W. M. Nau and U. Pischel, *Org. Biomol. Chem.*, 2015, 13, 2866.
- F.-J. Huo, C.-X. Yin and P. Yang, *Bioorg. Med. Chem. Lett.*, 2007, 17, 932.
- A. Rich and S. Zhang, *Nat. Rev. Genet.*, 2003, 4, 566.
- S.-R. Wang, J.-Q. Wang, G.-H. Xu, L. Wei, B.-S. Fu, L.-Y. Wu, Y.-Y. Song, X.-R. Yang, C. Li, S.-M. Liu and X. Zhou, *Adv. Sci.*, 2018, 5, 1800231.
- M. R. Cring and V. C. Sheffield, *Gene Ther.*, 2020, DOI: 10.1038/s41434-020-00197-8.
- (a) X. Guo and L. Huang, *Acc. Chem. Res.*, 2012, 45, 971; (b) *Pharmaceutical applications of dendrimers*, ed. A. Chauhan and H. Kulhari, Elsevier, Amsterdam, 1st edn, 2020; (c) M. A. Mintzer and E. E. Simanek, *Chem. Rev.*, 2009, 109, 259.
- X. Ma and Y. Zhao, *Chem. Rev.*, 2015, 115, 7794.
- Y.-B. Lim, T. Kim, J. W. Lee, S.-M. Kim, H.-J. Kim, K. Kim and J.-S. Park, *Biocjugate Chem.*, 2002, 13, 1181.
- Q. Huang, S. Li, Y.-F. Ding, H. Yin, L.-H. Wang and R. Wang, *Biomater. Sci.*, 2018, 6, 1031.
- S. K. Kim, K. M. Park, K. Singha, J. Kim, Y. Ahn, K. Kim and W. J. Kim, *Chem. Commun.*, 2010, 46, 692.
- W. Zhang, H.-Y. Zhang, Y.-H. Zhang and Y. Liu, *Chem. Commun.*, 2015, 51, 16127.
- R. K. Koninti, S. Sappati, S. Satpathi, K. Gavvala and P. Hazra, *ChemPhysChem*, 2016, 17, 506.
- K. Gavvala and S. Satpathi, *J. Lumin.*, 2016, 171, 234.
- S. Sun, Y. Yuan, Z. Li, S. Zhang, H. Zhang and X. Peng, *New J. Chem.*, 2014, 38, 3600.
- A. Manna and S. Chakravorti, *Spectrochim. Acta, Part A*, 2015, 150, 120.
- E. Y. Chernikova, A. Y. Ruleva, V. B. Tsvetkov, Y. V. Fedorov, V. V. Novikov, T. M. Aliyev, A. A. Pavlov, N. E. Shepel and O. A. Fedorova, *Org. Biomol. Chem.*, 2020, 18, 755.
- N. N. Alder, Fluorescence spectroscopy and its applications in analysing biomolecular processes, in *Biomolecular and Bioanalytical Techniques: Theory, Methodology and Applications*, ed. V. Ramesh, John Wiley & Sons, Chichester, 1st edn, 2019.
- H. K. Saeed, S. Sreedharan and J. A. Thomas, *Chem. Commun.*, 2020, 56, 1464.
- W. Chyan and R. T. Raines, *ACS Chem. Biol.*, 2018, 13, 1810.
- S. J. Smith, C. R. Nemer and S. O. Kelley, *J. Am. Chem. Soc.*, 2017, 139, 1020.
- W. J. Peveler and W. R. Algar, *ACS Chem. Biol.*, 2018, 13, 1752.
- S. Sinn and F. Biedermann, *Isr. J. Chem.*, 2018, 58, 357.
- F. Li, Y. Xu, H. Li, C. Wang, A. Lu and S. Sun, *New J. Chem.*, 2014, 38, 1396.
- N. Kitsera, M. Rodriguez-Alvarez, S. Emmert, T. Carell and A. Khobta, *Nucleic Acids Res.*, 2019, 47, 8537.
- J. L. Illuzzi and D. M. Wilson III, *Curr. Med. Chem.*, 2012, 19, 3922.
- Y. Zhou, L. Gao, X. Tong, Q. Li, Y. Fei, Y. Yu, T. Ye, X.-S. Zhou and Y. Shao, *Anal. Chem.*, 2018, 90, 13183.
- H. Liu, Z. Zhang, Y. Zhao, Y. Zhou, B. Xue, Y. Han, Y. Wang, X. Mu, S. Zang, X. Zhou and Z. Li, *J. Mater. Chem. B*, 2019, 7, 1435.



- 57 S. Zhang, K. I. Assaf, C. Huang, A. Hennig and W. M. Nau, *Chem. Commun.*, 2019, **55**, 671.
- 58 W. Ong, M. Gómez-Kaifer and A. E. Kaifer, *Org. Lett.*, 2002, **4**, 1791.
- 59 J. S. Bus, S. D. Aust and J. E. Gibson, *Biochem. Biophys. Res. Commun.*, 1974, **58**, 749.
- 60 S. Sun, W. Gao, F. Liu, J. Fan and X. Peng, *J. Mater. Chem.*, 2010, **20**, 5888.
- 61 S. Sun, Y. He, Z. Yang, Y. Pang, F. Liu, J. Fan, L. Sun and X. Peng, *Dalton Trans.*, 2010, **39**, 4411.
- 62 T. Zhang, S. Sun, F. Liu, Y. Pang, J. Fan and X. Peng, *Phys. Chem. Chem. Phys.*, 2011, **13**, 9789.
- 63 H.-B. Cheng, Y.-M. Zhang, C. Xu and Y. Liu, *Sci. Rep.*, 2014, **4**, 4210.
- 64 K. Uekama, F. Hirayama and H. Arima, Pharmaceutical applications of cyclodextrins and their derivatives, in *Cyclodextrins and Their Complexes: Chemistry, Analytical Methods, Applications*, Wiley-VCH, Weinheim, 2006.
- 65 A. I. Day and J. G. Collins, in *Supramolecular Chemistry: From Molecules to Nanomaterials*, ed. P. Gale and J. Steed, Wiley-VCH, Weinheim, 2012.
- 66 D. V. Berdnikova, T. M. Aliyev, T. Paululat, Y. V. Fedorov, O. A. Fedorova and H. Ihmels, *Chem. Commun.*, 2015, **51**, 4906.
- 67 C.-F. Ke, S. Hou, H.-Y. Zhang, Y. Liu, K. Yang and X.-Z. Feng, *Chem. Commun.*, 2007, 3374.
- 68 X.-J. Zhang, Y.-M. Zhang, Z. Wang, Y. Chen and Y. Liu, *ChemistrySelect*, 2016, **4**, 685.
- 69 A. Estévez-Torres and D. Baigl, *Soft Matter*, 2011, **7**, 6746.
- 70 C. K. Kwok and C. J. Merrick, *Trends Biotechnol.*, 2017, **35**, 997.
- 71 D. Rhodes and H. J. Lipps, *Nucleic Acids Res.*, 2015, **43**, 8627.
- 72 T. Tian, Y. Song, L. Wei, J. Wang, B. Fu, Z. He, X.-R. Yang, F. Wu, G. Xu, S.-M. Liu, C. Li, S. Wang and X. Zhou, *Nucleic Acids Res.*, 2017, **45**, 2283.
- 73 S. Satpathi, R. K. Singh, A. Mukherjee and P. Hazra, *Phys. Chem. Chem. Phys.*, 2018, **20**, 7808.
- 74 L. Q. Gu, O. Braha, S. Conlan, S. Cheley and H. Bayley, *Nature*, 1999, **398**, 686.
- 75 T. Li, L. Liu, Y. Li, J. Xie and H.-C. Wu, *Angew. Chem., Int. Ed.*, 2015, **54**, 7568.
- 76 B. Guo, Y. Sheng, K. Zhou, Q. Liu, L. Liu and H.-C. Wu, *Angew. Chem., Int. Ed.*, 2018, **57**, 3602.
- 77 X. Wu, B. Guo, Y. Sheng, Y. Zhang, J. Wang, S. Peng, L. Liu and H.-C. Wu, *Chem. Commun.*, 2018, **54**, 7673.
- 78 Z. Zhang, T. Li, Y. Sheng, L. Liu and H.-C. Wu, *Small*, 2019, **15**, 1804078.
- 79 L. Liu, T. Li, S. Zhang, P. Song, B. Guo, Y. Zhao and H.-C. Wu, *Angew. Chem., Int. Ed.*, 2018, **57**, 11882.
- 80 T. Zeng, L. Liu, T. Li, Y. Li, J. Gao, Y. Zhao and H.-C. Wu, *Chem. Sci.*, 2015, **6**, 5628.
- 81 L. Liu, Y. Li, T. Li, J. Xie, C. Chen, Q. Liu, S. Zhang and H.-C. Wu, *Anal. Chem.*, 2016, **88**, 1073.
- 82 L. Liu, Y. You, K. Zhou, B. Guo, Z. Cao, Y. Zhao and H.-C. Wu, *Angew. Chem., Int. Ed.*, 2019, **58**, 14929.
- 83 Y. You, K. Zhou, B. Guo, Q. Liu, Z. Cao, L. Liu and H.-C. Wu, *ACS Sens.*, 2019, **4**, 774.
- 84 S. Singh, A. Deep, G. Mohanta and V. K. Meena, in *Developments in the electrochemical bionanosensors for the predictive diagnosis of prostate and breast cancer*, ed. P. Chandra, Springer Nature Singapore Pte Ltd, 2017.
- 85 M. Wiemann and P. Jonkheijm, *Isr. J. Chem.*, 2018, **58**, 314.
- 86 S. Yang, M. You, L. Yang, F. Zhang, Q. Wang and P. He, *J. Electroanal. Chem.*, 2016, **783**, 161.
- 87 Y. Chang, Y. Zhuo, Y. Chai and R. Yuan, *Anal. Chem.*, 2017, **89**, 8266.
- 88 R. Sasmal, N. D. Saha, M. Pahwa, S. Rao, D. Joshi, M. S. Inamdar, V. Sheeba and S. S. Agasti, *Anal. Chem.*, 2018, **90**, 11305.
- 89 S.-R. Wang, Y.-Y. Song, L. Wei, C.-X. Liu, B.-S. Fu, J.-Q. Wang, X.-R. Yang, Y.-N. Liu, S.-M. Liu, T. Tian and X. Zhou, *J. Am. Chem. Soc.*, 2017, **139**, 16903.
- 90 X. Zhou, X. Su, P. Pathak, R. Vik, B. Vinciguerra, L. Isaacs and J. Jayawickramarajah, *J. Am. Chem. Soc.*, 2017, **139**, 13916.
- 91 Z. Yu, M. Ai, S. K. Samanta, F. Hashiya, J. Taniguchi, S. Asamitsu, S. Ikeda, K. Hashiya, T. Bando, G. N. Pandian, L. Isaacs and H. Sugiyama, *Chem. Commun.*, 2020, **56**, 2296.
- 92 N. Dubel, S. Liese, F. Scherz and O. Seitz, *Angew. Chem., Int. Ed.*, 2019, **58**, 907.
- 93 S. Pandey, D. V. D. W. Kankanamalage, X. Zhou, C. Hu, M. E. Hoque, L. Isaacs, J. Jayawickramarajah and H. Mao, *J. Am. Chem. Soc.*, 2019, **141**, 18385.
- 94 C. Li, M. J. Rowland, Y. Shao, T. Cao, C. Chen, H. Jia, X. Zhou, Z. Yang, O. A. Scherman and D. Liu, *Adv. Mater.*, 2015, **27**, 3298.
- 95 T. Du, W. Yuan, Z. Zhao and S. Liu, *Chem. Commun.*, 2019, **55**, 3658.
- 96 W. Yuan, J. Ma, Z. Zhao and S. Liu, *Macromol. Rapid Commun.*, 2020, **41**, 2000022.
- 97 Z. Li, S. Sun, Z. Yang, S. Zhang, H. Zhang, M. Hu, J. Cao, J. Wang, F. Liu, F. Song, J. Fan and X. Peng, *Biomaterials*, 2013, **34**, 6473.
- 98 P. A. Sharp, RNA interference – 2001, *Genes Dev.*, 2001, **15**, 485.
- 99 B. Hu, L. Zhong, Y. Weng, L. Peng, Y. Huang, Y. Zhao and X.-J. Liang, *Signal Transduction Targeted Ther.*, 2020, **5**, 101.
- 100 F. Li, M. Wang, S. Guan, Z. Huang, S. Liu, X. Li, X. Jiang, Q. Luo, J. Xu and J. Liu, *Polym. Chem.*, 2019, **10**, 5659.
- 101 Y.-M. Zhang, Y. Yang, Y.-H. Zhang and Y. Liu, *Sci. Rep.*, 2016, **6**, 28848.
- 102 (a) K. D. Warner, C. E. Hajdin and K. M. Weeks, *Nat. Rev. Drug Discovery*, 2018, **17**, 547; (b) N. F. Rizvi and G. F. Smith, *Bioorg. Med. Chem. Lett.*, 2017, **27**, 5083; (c) J. R. Thomas and P. J. Hergenrother, *Chem. Rev.*, 2008, **108**, 1171.

